Platelet 5-HT uptake sites, labelled with [3H] paroxetine, in controls and depressed patients before and after treatment with fluoxetine or lofepramine

• Published in: Psychopharmacologia Vol. 115; no. 1-2; pp. 261 - 264
• Main Authors: LAWRENCE, K. M, KATONA, C. L. E, ABOU-SALEH, M. T, ROBERTSON, M. M, NAIRAC, B. L, EDWARDS, D. R. L, BURNS, R. A, HARRISON, D. A, HORTON, R. W
• Format: Journal Article
• Language: English
• Published: Berlin Springer 01-06-1994
• Subjects: Adolescent; Adult; Aged; Biological and medical sciences; Blood Platelets - drug effects; Blood Platelets - metabolism; Cell Membrane - drug effects; Cell Membrane - metabolism; Depressive Disorder - blood; Depressive Disorder - drug therapy; Depressive Disorder - psychology; Double-Blind Method; Female; Fluoxetine - blood; Fluoxetine - pharmacokinetics; Fluoxetine - therapeutic use; Humans; Lofepramine - blood; Lofepramine - pharmacokinetics; Lofepramine - therapeutic use; Male; Medical sciences; Middle Aged; Neuropharmacology; Paroxetine - blood; Paroxetine - pharmacokinetics; Paroxetine - therapeutic use; Pharmacology. Drug treatments; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease); Psychology. Psychoanalysis. Psychiatry; Psychopharmacology; Receptors, Serotonin - drug effects; Receptors, Serotonin - metabolism; Human; Serotonin; Psychotropic; Treatment efficiency; Biological marker; Tricyclic compound; Reuptake inhibitor; Chemotherapy; Biological fixation; Platelet; Neuromediator; Double blind study; Antidepressant agent; Norepinephrine
• ISSN: 0033-3158; 1432-2072
• DOI: 10.1007/BF02244781

Platelet [3H] paroxetine binding was measured in 73 depressed patients and in 64 healthy volunteers. No differences were found in Bmax or Kd either overall, or when the 61 depressed subjects who had never received psychotropic drugs were analysed separately. Within the depressed group, no differences in Bmax or Kd were found between subgroups divided on the basis of endogenicity, suicidal thoughts or severity of depression. None of the subgroups differed significantly from controls. Forty of the depressed subjects were retested after 6 weeks' treatment with fluoxetine (n = 22) or lofepramine (n = 18). Treatment was not associated with any change in Bmax but a similar and significant increase in Kd was noted following treatment with either antidepressant. Neither pre- nor post-treatment platelet binding parameters appeared to relate to clinical response to treatment.